Review article: New-onset diabetes after transplantation.
This article reviews the clinical aspects and epidemiological links between diabetes mellitus and renal transplantation, and emphasizes areas that warrant further clarification. In particular, we summarize the data for various immunosuppression medications on the risk of new-onset diabetes after transplantation (NODAT). An increased mechanistic understanding of new-onset diabetes might provide new insights into the pathophysiology of this complication after solid organ transplantation. Claims that selecting immunosuppression regimen to minimize the risk of NODAT, nevertheless, are currently not supported by the scientific published work. Intuitively, strategies that aim to change the underlying biology of the disease process of NODAT are desirable; among them, lifestyle modification is currently the most promising in terms of real benefit with the least risk.
Chow
Kai Ming
KM
Department of Medicine and Therapeutics, Division of Nephrology, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China.
Li
Philip Kam-Tao
PK
D003920:Diabetes Mellitus / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy; D018450:Disease Progression; D019317:Evidence-Based Medicine; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016030:Kidney Transplantation / Q000009:adverse effects*; D018570:Risk Assessment; D012307:Risk Factors; D040242:Risk Reduction Behavior
D007166:Immunosuppressive Agents